Caprylidene

From Self-sufficiency
Jump to: navigation, search
Caprylidene
260px
260px
Systematic (IUPAC) name
[2-octanoyloxy-1-(octanoyloxymethyl)ethyl] octanoate
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Identifiers
ATC code None
PubChem CID 10850
ChemSpider 10393
Synonyms Glycerol trioctanoate
Chemical data
Formula C27H50O6
Molar mass 470.68 g · mol−1[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Caprylidene (trade name Axona) is a medical food that was approved in March 2009 by the U.S. Food and Drug Administration for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease".[1] Glucose metabolism by the brain is impaired in Alzheimer's disease, and it is proposed that ketone bodies may provide an alternative energy source. Caprylidene is a powdered form of caprylic triglyceride, a medium chain triglyceride (MCT) in which three molecules of caprylic acid are esterified with glycerol.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. FDA-Approved Drugs 2009: Axona (caprylidene) CenterWatch. Cited 30 November 2009.
  2. Axona Drugs.com. Cited 30 November 2009.